Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
HealthDay on MSN15h
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionThe U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback